Literature DB >> 33111165

Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules.

Maria Stella Franzè1, Antonio Bottari2, Simona Caloggero3, Alessia Pitrone3, Adalberto Barbera4, Tindaro Lembo1,5, Gaia Caccamo1, Irene Cacciola6, Sergio Maimone1, Angela Alibrandi7, Concetta Pitrone1, Giovanni Squadrito8, Giovanni Raimondo1,6, Carlo Saitta9.   

Abstract

Ultrasound (US) detection of liver nodules in cirrhotic patients requires further radiological examinations and often a follow-up with repeated short-term evaluations to verify the presence of hepatocellular carcinoma (HCC). Aims of the study were to assess the rate of HCC diagnosis and to identify HCC predictors in a cohort of cirrhotics followed-up after US detection of the liver nodule(s). One-hundred-eighty-eight consecutive cirrhotic patients (124 males, mean age 64.2 years) with liver nodule(s) detected by US were enrolled. All patients underwent second-level imaging [computed tomography (TC) or magnetic resonance (MR)], and those without a definite diagnosis of HCC were followed-up with TC and/or RM repeated every 3-6 months up to 18 months if HCC was not diagnosed. After 18 months, non-HCC patients came back to routine US surveillance. HCC was diagnosed in 73/188 cases (38.8%). In 66/73 patients (90.4%) HCC was identified at first radiological evaluation after US, while in the remaining seven subjects it was diagnosed at the subsequent imaging examination. Age (p = 0.001) and nodule dimension (p = 0.0001) were independent predictors of HCC at multivariate analysis. Fourty-nine/188 patients were lost at follow up after 18 months. Twenty/139 remaining patients developed HCC and 3/139 cholangiocarcinoma; 77 died between 3 and 110 months from the beginning of the study (61 for end-stage liver disease, 8 for extrahepatic causes, eight for unknown causes). Patients who developed liver cancer earlier during the follow up had the shortest overall survival. US-detected liver nodules are not neoplastic in more than half of cirrhotic patients. A definite diagnosis may be obtained at the time of the first radiologic evaluation after US in the vast majority of the cases. Patients in whom nodules are found not to be tumoral may return to the US surveillance program routinely applied to all cirrhotics.

Entities:  

Keywords:  Cirrhosis; HCC; Liver nodules; Surveillance; Ultrasound

Year:  2020        PMID: 33111165     DOI: 10.1007/s11739-020-02541-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  15 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

2.  Improved survival with screening for hepatocellular carcinoma.

Authors:  L L Wong; W M Limm; R Severino; L M Wong
Journal:  Liver Transpl       Date:  2000-05       Impact factor: 5.799

Review 3.  Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media.

Authors:  A Rosado Ingelmo; I Doña Diaz; R Cabañas Moreno; M C Moya Quesada; C García-Avilés; I García Nuñez; J I Martínez Tadeo; R Mielgo Ballesteros; N Ortega-Rodríguez; M A Padial Vilchez; L Sánchez-Morillas; C Vila Albelda; E Moreno Rodilla; M J Torres Jaén
Journal:  J Investig Allergol Clin Immunol       Date:  2016       Impact factor: 4.333

4.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

Review 5.  Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis.

Authors:  Morris Sherman
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study.

Authors:  B J McMahon; L Bulkow; A Harpster; M Snowball; A Lanier; F Sacco; E Dunaway; J Williams
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

7.  Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

Authors:  Norihiro Kokudo; Nobuyuki Takemura; Kiyoshi Hasegawa; Tadatoshi Takayama; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Namiki Izumi; Shuichi Kaneko; Masatoshi Kudo; Hiroko Iijima; Takuya Genda; Ryosuke Tateishi; Takuji Torimura; Hiroshi Igaki; Satoshi Kobayashi; Hideyuki Sakurai; Takamichi Murakami; Takeyuki Watadani; Yutaka Matsuyama
Journal:  Hepatol Res       Date:  2019-09-06       Impact factor: 4.288

Review 8.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

9.  Effects of contrast media on renal function in patients with cirrhosis: a prospective study.

Authors:  Mònica Guevara; Glòria Fernández-Esparrach; Carlo Alessandria; Aldo Torre; Carlos Terra; Xavier Montañà; Carlos Piera; Maria Luisa Alvarez; Wladimiro Jiménez; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

10.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.